PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema… Read more
PHARVARIS N.V. EO -12 (9EN) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, PHARVARIS N.V. EO -12 (9EN) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
PHARVARIS N.V. EO -12 - Net Assets Trend (None–None)
This chart illustrates how PHARVARIS N.V. EO -12's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PHARVARIS N.V. EO -12 (None–None)
The table below shows the annual net assets of PHARVARIS N.V. EO -12 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to PHARVARIS N.V. EO -12's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
PHARVARIS N.V. EO -12 Competitors by Market Cap
The table below lists competitors of PHARVARIS N.V. EO -12 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Converge Technology Solutions Corp
OTCQX:CTSDF
|
$790.23 Million |
|
Unilumin Group Co Ltd
SHE:300232
|
$790.59 Million |
|
COURSERA INC. DL -00001
F:90E
|
$790.62 Million |
|
Thurgauer Kantonalbank
SW:TKBP
|
$790.68 Million |
|
Barings BDC Inc
NYSE:BBDC
|
$789.88 Million |
|
BANGCHAK CORP. -FGN- BA 1
F:7BP
|
$789.82 Million |
|
TXC Corp
TW:3042
|
$789.61 Million |
|
Shanxi Lanhua Sci-Tech Venture Co Ltd
SHG:600123
|
$789.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PHARVARIS N.V. EO -12's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares PHARVARIS N.V. EO -12's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently PHARVARIS N.V. EO -12 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares PHARVARIS N.V. EO -12's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PHARVARIS N.V. EO -12 (9EN) | €- | N/A | N/A | $790.20 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |